Women are disproportionately affected by gonorrhoea, frequently remaining asymptomatic until severe complications like pelvic inflammatory disease or infertility arise. Traditional preclinical models fall short of reprod...

Managing post-marketing pharmacovigilance across global markets presents significant challenges, from meeting local regulatory requirements to ensuring timely safety reporting and oversight. In this article, Quintin van ...

As regulatory expectations for biosimilars continue to evolve, bioanalytical strategy is becoming increasingly important in demonstrating biosimilarity. In this BioProcess International article, authors Kimberly Salgado...

How can sponsors generate meaningful clinical insights earlier in neurodegenerative disease development? Join ICON specialists Paula Kopschina Feltes and Matthias Mohse as they explore innovative first-in-human study des...

We are delighted to welcome 19 newly recruited graduates to ICON in Japan. The group were welcomed by the Ambassador of Ireland to Japan, Noel White, alongside ICON Japan senior management. The Ambassador spoke to the g...

Hear the latest updates and insights on clinical trial operations from the Accellacare team of professionals at the #GSSS this October 15-18. Meet us at the Signia by Hilton Orlando Bonnet Creek, booth \#406. https://ow....

Which audience will be most interested in your research? Find out with PubsHub Journals & Congresses. Over 10,000 journals and conferences to consider and incorporate 50+ accessible points of metadata to provide the answ...

As oncology programs evolve, biotechs need more than scientific momentum. They need agile execution, flexible resourcing and strategies that keep pace with changing development demands. Meet the ICON Biotech and Oncology...

The pressure to make confident development decisions earlier has never been greater. Discover how innovative early phase trial designs, patient engagement strategies, and biomarker insights are helping sponsors navigate ...

For pharmaceutical and medtech organisations, PPWR compliance extends far beyond sustainability goals. Packaging changes may affect labelling, supplier qualification, regulatory submissions and operational timelines. In...

Attending the 15th World CB & CDx Summit, 5 – 8 October in Boston? Meet our team at booth \#4 to learn how ICON’s biomarker expertise drives smarter trials, accelerates CDx strategies & delivers patient impact.

From first-in-human studies through pivotal and post-market programmes, cardiovascular innovation demands deep therapeutic and operational expertise. ICON's MDDR team has extensive experience supporting cardiovascular d...